<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Patwardhan CA</submitter><funding>NIGMS NIH HHS</funding><pagination>223-9</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4836055</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>20(2)</volume><pubmed_abstract>Hsp90 and its co-chaperones are known to be important for cancer cell survival. The N-terminal inhibitors of Hsp90 that are in ongoing clinical trials as antitumor agents have unfortunately shown disappointing efficacies in the clinic. Thus, novel inhibitors of the Hsp90 machine with a different mechanism of action are urgently needed. We report here the development of a novel high-throughput screening assay platform to identify small-molecule inhibitors of Hsp90 and its co-chaperones. This assay quantitatively measures the ability of Hsp90 and its co-chaperones to refold/protect the progesterone receptor, a physiological client of Hsp90, in a 96-well plate format. We screened the National Institutes of Health clinical collection drug library and identified capsaicin as a hit molecule. Cap</pubmed_abstract><journal>Journal of biomolecular screening</journal><pubmed_title>Progesterone receptor chaperone complex-based high-throughput screening assay: identification of capsaicin as an inhibitor of the Hsp90 machine.</pubmed_title><pmcid>PMC4836055</pmcid><funding_grant_id>R01 GM102443</funding_grant_id><funding_grant_id>GM102443-01</funding_grant_id><pubmed_authors>Patwardhan CA</pubmed_authors><pubmed_authors>Chadli A</pubmed_authors><pubmed_authors>Alfa E</pubmed_authors><pubmed_authors>Lu S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Progesterone receptor chaperone complex-based high-throughput screening assay: identification of capsaicin as an inhibitor of the Hsp90 machine.</name><description>Hsp90 and its co-chaperones are known to be important for cancer cell survival. The N-terminal inhibitors of Hsp90 that are in ongoing clinical trials as antitumor agents have unfortunately shown disappointing efficacies in the clinic. Thus, novel inhibitors of the Hsp90 machine with a different mechanism of action are urgently needed. We report here the development of a novel high-throughput screening assay platform to identify small-molecule inhibitors of Hsp90 and its co-chaperones. This assay quantitatively measures the ability of Hsp90 and its co-chaperones to refold/protect the progesterone receptor, a physiological client of Hsp90, in a 96-well plate format. We screened the National Institutes of Health clinical collection drug library and identified capsaicin as a hit molecule. Cap</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Feb</publication><modification>2025-04-04T11:40:58.784Z</modification><creation>2019-03-27T02:11:53Z</creation></dates><accession>S-EPMC4836055</accession><cross_references><pubmed>25184514</pubmed><doi>10.1177/1087057114549147</doi></cross_references></HashMap>